• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Novel approaches to antiplatelet therapy
Biochem Pharmacol. 2022 Oct 12:115297. doi: 10.1016/j.bcp.2022.115297. Online ahead of print.ABSTRACTPlatelets are the main effectors of the thrombotic events occurring at a ruptured atherosclerotic plaque and therefore antiplatelet agents are the mainstay of antithrombotic treatment for the prevention of myocardial infarction, atherotrombotic ischemic stroke and critical limb ischemia due to the thrombotic occlusion of the peripheral arteries. Despite great progress in antiplatelet agents over the last two decades, a number of important unmet medical needs still remain, like insufficient efficacy and a high incidence of h...
Source: Biochemical Pharmacology - October 15, 2022 Category: Drugs & Pharmacology Authors: Paolo Gresele Stefania Momi Source Type: research

Snake venom three-finger toxins and their potential in drug development targeting cardiovascular diseases.
Abstract Cardiovascular diseases such as coronary and peripheral artery diseases, venous thrombosis, stroke, hypertension, and heart failure are enormous burden to health and economy globally. Snake venoms have been the sources of discovery of successful therapeutics targeting cardiovascular diseases. For example, the first-in-class angiotensin-converting enzyme inhibitor captopril was designed largely based on bradykinin-potentiating peptides from Bothrops jararaca venom. In the recent years, sensitive and high throughput approaches drive discovery and cataloging of new snake venom toxins. As one of the largest c...
Source: Biochemical Pharmacology - June 20, 2020 Category: Drugs & Pharmacology Authors: Manjunatha Kini R, Yeow Koh C Tags: Biochem Pharmacol Source Type: research

The therapeutic potential of purinergic signalling.
Abstract This review is focused on the pathophysiology and therapeutic potential of purinergic signalling. A wide range of diseases are considered, including those of the central nervous system, skin, kidney, musculoskeletal, liver gut, lower urinary tract, cardiovascular, airways and reproductive systems, the special senses, infection, diabetes and obesity. Several purinergic drugs are already on the market, including P2Y12 receptor antagonists for stroke and thrombosis, P2Y2 receptor agonists for dry eye, A1 receptor agonists for supraventricular tachycardia. Clinical trials are underway for the use of P2X3 rece...
Source: Biochemical Pharmacology - July 20, 2017 Category: Drugs & Pharmacology Authors: Burnstock G Tags: Biochem Pharmacol Source Type: research

Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase.
In conclusion, this study indicates that both alteplase and tenecteplase cause plasmin-mediated proteolysis of apoA-I, with alteplase resulting in a greater apoA-I degradation than tenecteplase, potentially causing a transient impairment of HDL atheroprotective functions. PMID: 23219857 [PubMed - as supplied by publisher]
Source: Biochemical Pharmacology - December 5, 2012 Category: Drugs & Pharmacology Authors: Gomaraschi M, Ossoli A, Vitali C, Pozzi S, Vitali Serdoz L, Pitzorno C, Sinagra G, Franceschini G, Calabresi L Tags: Biochem Pharmacol Source Type: research